ImmuCell Reports 46% Q3 Sales Growth to $8 Million
ImmuCell Corporation (ICCC) announced preliminary third-quarter 2026 total sales of $8.0 million, marking a 46% increase compared to the same period in 2025. Domestic sales rose 29.2% year-over-year to $6.9 million, bringing total sales for the first nine months of the year to $25.6 million, a 27.8% gain over the prior-year period.
The revenue expansion was supported by a larger sales team, stronger commercial execution, and improved manufacturing reliability that allowed the company to meet customer demand and address prior production backlogs. Product line growth was broad-based during the quarter, led by a 51% increase in Tri-Shield sales, a 36% rise in Dual-Force sales, and a 37% gain for the recently launched functional feed line. Comparative growth figures were also aided by depressed sales in the third quarter of 2025, which had followed unusually high distributor purchasing in the second quarter of that year.
Looking ahead, ImmuCell is ending its practice of providing early sales updates and will present revenue alongside full financial metrics during standard quarterly events. Complete third-quarter financial results will be discussed during a scheduled conference call on November 13, 2026.
Key points
- ImmuCell Corporation recorded Q3 2026 total sales of $8.0 million, up 46% year-over-year.
- Nine-month sales reached $25.6 million, representing a 27.8% gain over the same period in 2025.
- Product growth was led by Tri-Shield with a 51% sales increase, while Dual-Force grew 36% and the functional feed line rose 37%.
- Higher manufacturing reliability and sales team expansion helped resolve earlier supply backlogs and drive higher volume.
- The company will discontinue early sales reports and release full quarterly financial results on November 13, 2026.
Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org
How we writeDisclaimerQuestions and answers
What were ImmuCell's Q3 2026 sales?
ImmuCell reported preliminary total sales of $8.0 million for Q3 2026, representing a 46% increase compared to the same period in 2025. Domestic sales reached $6.9 million.
What factors drove ImmuCell's sales growth in Q3 2026?
Sales growth was driven by sales team expansion, improved commercial execution, and better manufacturing reliability that helped meet customer demand. Sales of Tri-Shield grew 51%, Dual-Force rose 36%, and the new functional feed line increased 37%.
When will ImmuCell report full third-quarter financial results?
ImmuCell is ending preliminary sales updates and will present complete financial metrics during a conference call scheduled for November 13, 2026.